Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting KIT with tyrosine kinase inhibitors (TKIs) sunitinib a...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrano, César, Mariño-Enríquez, Adrián, Tao, Derrick L., Ketzer, Julia, Eilers, Grant, Zhu, Meijun, Yu, Channing, Mannan, Aristotle M., Rubin, Brian P., Demetri, George D., Raut, Chandrajit P., Presnell, Ajia, McKinley, Arin, Heinrich, Michael C., Czaplinski, Jeffrey T., Sicinska, Ewa, Bauer, Sebastian, George, Suzanne, Fletcher, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462042/
https://www.ncbi.nlm.nih.gov/pubmed/30792533
http://dx.doi.org/10.1038/s41416-019-0389-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462042/
https://www.ncbi.nlm.nih.gov/pubmed/30792533
http://dx.doi.org/10.1038/s41416-019-0389-6

Ejemplares similares